(Total Views: 353)
Posted On: 02/11/2019 10:54:23 AM
Post# of 72446
Dr. B putting himself out there again...
“We are active in advanced discussions with a variety of pharmaceuticals companies. Our goal remains to secure a partner for advanced clinical development of Brilacidin as a new therapeutic for Oral Mucositis and Inflammatory Bowel Disease. At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”
Getting this first deal done is the combination to the safe.
https://finance.yahoo.com/news/innovation-pha...00999.html
“We are active in advanced discussions with a variety of pharmaceuticals companies. Our goal remains to secure a partner for advanced clinical development of Brilacidin as a new therapeutic for Oral Mucositis and Inflammatory Bowel Disease. At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”
Getting this first deal done is the combination to the safe.
https://finance.yahoo.com/news/innovation-pha...00999.html
(4)
(0)
